Drug Trial Radar · NCT04942067
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
108
Planned (sponsor's estimate)
Start
Dec 23, 2021
Primary completion
Sep 1, 2024
Study completion Dec 1, 2024
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent
Conditions
- Multiple Myeloma
- Amyloidosis
Interventions
APG-2575+ PdDrug
APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
APG-2575 + DRdDrug
APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicityTime frame: 28 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Jacksonville, Florida · Recruiting
Weil Cornell Medical Center
New York, New York · Recruiting
Cleveland Clinic Hosptials
Cleveland, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.